Cargando…

Clinical Impact of Liraglutide as a Treatment of Obesity

Obesity is defined as a chronic, complex, relapsing disease characterized by excessive adipose tissue. Obesity impacts an individual’s health by increasing complications such as prediabetes, type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, metabolic syndrome, cardiovascular disease, nona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alruwaili, Heshma, Dehestani, Babak, le Roux, Carel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958997/ https://www.ncbi.nlm.nih.gov/pubmed/33732030 http://dx.doi.org/10.2147/CPAA.S276085

Ejemplares similares

Amylin as a Future Obesity Treatment
por: Dehestani, Babak, et al.
Publicado: (2021)

The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers
por: Dehestani, Babak, et al.
Publicado: (2019)

Liraglutide: another reason to target prediabetes?
por: Murphy, Conor F., et al.
Publicado: (2017)

A review of the evidence on cardiovascular outcomes from obesity treatment
por: Abdul Wahab, Roshaida, et al.
Publicado: (2023)

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
por: Seo, Young-Gyun
Publicado: (2021)

The Relationship Between Percentage Weight Loss and World Health Organization-Five Wellbeing Index (WHO-5) in Patients Having Bariatric Surgery
por: Abdul Wahab, Roshaida, et al.
Publicado: (2022)

Liraglutide and obesity: a review of the data so far
por: Ladenheim, Ellen E
Publicado: (2015)

How do patients’ clinical phenotype and the physiological mechanisms of the operations impact the choice of bariatric procedure?
por: Bächler, Thomas, et al.
Publicado: (2016)

Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
por: Coelho, Claudia, et al.
Publicado: (2023)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

The Concept of Healthy Behaviours in Obesity May Have Unintended Consequences
por: Craig, Hilary C., et al.
Publicado: (2022)

The Neurobiological Impact of Ghrelin Suppression after Oesophagectomy
por: Murphy, Conor F., et al.
Publicado: (2016)

Recent advances in the treatment of patients with obesity and chronic kidney disease
por: Abdul Wahab, Roshaida, et al.
Publicado: (2023)

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives
por: Edavalath, Mahamood, et al.
Publicado: (2010)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
por: Kim, Sun H., et al.
Publicado: (2013)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
por: Carlsson Petri, Kristin C., et al.
Publicado: (2021)

Efficacy and safety of liraglutide in Indian adolescents with obesity
por: Kochar, I. S., et al.
Publicado: (2019)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

How Ethical Is Our Current Delivery of Care to Patients with Severe and Complicated Obesity?
por: Craig, Hilary, et al.
Publicado: (2018)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato, Mauro, et al.
Publicado: (2014)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy
por: Sudlow, Alexis, et al.
Publicado: (2019)

Effects of liraglutide on obesity-associated functional hypogonadism in men
por: Jensterle, M, et al.
Publicado: (2019)

Liraglutide restores impaired associative learning in individuals with obesity
por: Hanssen, Ruth, et al.
Publicado: (2023)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Obesity Characteristics Are Poor Predictors of Genetic Mutations Associated with Obesity
por: Al-Humadi, Ahmed W., et al.
Publicado: (2023)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

COVID-19 alters thinking and management in metabolic diseases
por: le Roux, Carel W.
Publicado: (2020)

Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
por: Cuomo, Alessandro, et al.
Publicado: (2019)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
por: Wronka, Magdalena, et al.
Publicado: (2023)

Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
por: Cohen, Ricardo V., et al.
Publicado: (2021)

Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide for the treatment of obesity
por: Yaneva, Martina, et al.
Publicado: (2023)

Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
por: Papamargaritis, Dimitris, et al.
Publicado: (2021)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ncv97cc4ob93a5mf53epee8olh